VFINX
Price
$698.88
Change
+$11.51 (+1.67%)
Updated
Jun 15 closing price
Net Assets
1.7T
VNSAX
Price
$24.41
Change
+$0.39 (+1.62%)
Updated
Jun 15 closing price
Net Assets
565.98M
Interact to see
Advertisement

VFINX vs VNSAX

Header iconVFINX vs VNSAX Comparison
Open Charts VFINX vs VNSAXBanner chart's image
VFINX vs VNSAX Comparison Chart in %
View a ticker or compare two or three
VS
VFINX vs. VNSAX commentary
Jun 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is VFINX is a Buy and VNSAX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VFINX has more cash in the bank: 1.7T vs. VNSAX (566M). VFINX pays higher dividends than VNSAX: VFINX (0.93) vs VNSAX (0.00). VFINX was incepted earlier than VNSAX: VFINX (50 years) vs VNSAX (14 years). VNSAX (1.09) is less costly to investors than VFINX (0.14). VNSAX is a more actively managed with annual turnover of: 64.00 vs. VFINX (2.00). VFINX has a lower initial minimum investment than VNSAX: VFINX (0) vs VNSAX (2500). VFINX annual gain was more profitable for investors over the last year : 24.36 vs. VNSAX (10.18). VFINX return over 5 years is better than : 76.06 vs. VNSAX (6.33).
VFINXVNSAXVFINX / VNSAX
Total Expense Ratio0.141.0913%
Annual Report Gross Expense Ratio0.141.0913%
Fund Existence50 years14 years-
Gain YTD8.7807.041125%
Front LoadN/A6%-
Min. Initial Investment02500-
Min. Initial Investment IRAN/AN/A-
Net Assets1.7T566M300,707%
Annual Yield % from dividends0.930.00-
Returns for 1 year24.3610.18239%
Returns for 3 years68.6029.28234%
Returns for 5 years76.066.331,202%
Returns for 10 years258.7467.58383%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TXMD2.290.09
+4.09%
TherapeuticsMD
KLIC115.432.30
+2.04%
Kulicke and Soffa Industries
GOLD43.66-0.57
-1.29%
Gold.com Inc.
PCYO10.57-0.16
-1.49%
Pure Cycle Corp
GSK52.23-0.81
-1.53%
GSK plc